Metabolic Solutions

What Metabolic Solutions does

Founded in 1992 and headquartered in Nashua, New Hampshire, Metabolic Solutions is a privately held laboratory services company specializing in stable isotope tracer analysis for metabolic research. The firm operates a Gas Chromatography Combustion Isotope Ratio Mass Spectrometry (GCC-IRMS) platform that quantifies metabolic biomarkers using carbon-13 (13C), nitrogen-15 (15N), deuterium (2H), and oxygen-18 (18O) tracers, with detection precision reaching 0.001% deuterium enrichment. Its proprietary Deuteromics approach enables simultaneous measurement of glucose, lipid, and protein flux from a single oral D2O dose, removing the need for constant tracer infusion. The full assay menu covers de novo lipogenesis, muscle protein synthesis, glucose kinetics, energy expenditure, total body water, amino acid and protein turnover, cell proliferation, fibrosis and collagen turnover, rare disease and gene therapy endpoints, and targeted protein half-life. All regulated research assays are delivered under GLP compliance with CLIA certification, 21 CFR Part 11 data handling, and HIPAA-aligned PHI controls, making the output suitable for inclusion in FDA submissions.

The company's revenue model is two-sided. On the B2B side, it sells quote-based multi-year research services to pharmaceutical and biotech drug development programs; the published client list includes Pfizer, Eli Lilly, Genentech, Insitro, Moderna, Novartis, Merck, Regeneron, Amgen, Gilead Sciences, Korro Bio, and TNO, plus academic medical centers such as Mass General Brigham, Cleveland Clinic, and Mayo Clinic. On the consumer and clinical side, it markets at-home GI breath test kits under the Gut-Chek sub-brand through its shop.metsol.com e-commerce storefront and a dedicated healthcare-provider storefront, with kits priced at $129–$139 per unit for SIBO, lactose intolerance, fructose malabsorption, H. pylori, and leaky gut assessment. Distribution is direct in both channels, with senior-scientist-led consultation driving enterprise sales. Operating geographies are primarily North America (USA), and the company is led by CEO Adnan Fakhoury. There are no disclosed funding rounds, parent companies, or M&A activity in the available record.

Metabolic Solutions' competitive position rests on (i) 35+ years of exclusive focus on stable isotope methodology, (ii) a regulatory stack (GLP/CLIA/Part 11) that is rare for a specialist lab, (iii) cumulative experience across more than 1,000 studies guiding clients from protocol design to FDA submission, and (iv) turnaround metrics pitched at protocol design within 48 hours and delivery weeks faster than general CROs. The principal strategic risks are customer concentration in a small number of large pharma programs, dependence on a single physical laboratory, and absence of disclosed headcount or revenue growth data to verify the pace of expansion.

Name

Metabolic Solutions

Legal name

Metabolic Solutions, LLC.

Website

https://metsol.com

Company type

Private

Founded year

1992

Operating status

Operating

Headcount range

1–10 employees

Short description

Metabolic Solutions is a Nashua, NH-based GLP/CLIA-certified laboratory providing stable isotope tracer (GCC-IRMS) analysis for pharmaceutical drug development programs, plus its Gut-Chek line of direct-to-consumer at-home GI breath tests for SIBO, lactose intolerance, and H. pylori.

Ownership category

akta.pro rank

Product category

Bioanalytical / Clinical Laboratory Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical and Diagnostic Laboratories (6215)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Bioanalytical & Biomarker CROs (PK/PD/Immunogenicity) (HLAGAAAD)

akta.pro secondary industries

DMPK / ADME & Bioanalysis (HLAGAFAC), Bioanalytical Testing (PK/ADA/NAb) (HLAGADAA), Metabolomics & Lipidomics Services (HLAGANAG)

Keywords

• Stable isotope analysis
• Metabolic research services
• Pharmaceutical bioanalytical
• GI breath testing
• Mass spectrometry services

Headquarters

HQ city

Nashua

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales, Supply Chain

Revenue model

1. Pharmaceutical & Biotech Research Services: B2B stable isotope analysis services for pharma/biotech drug development programs across preclinical and clinical stages. Services include assay design, tracer kit provision, sample analysis, and regulatory-ready reporting.
2. GI Breath Test Kits (Direct-to-Consumer & Provider): Sale of at-home breath test kits for lactose intolerance, fructose malabsorption, SIBO, H. pylori, and leaky gut to consumers and healthcare providers via shop.metsol.com and clinical sales channel.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels3 records

Core offering

Metabolic Solutions is a bioanalytical laboratory that provides contract stable isotope tracer analysis services to pharmaceutical and biotechnology companies for metabolic research and drug development, spanning De Novo Lipogenesis, Muscle Protein Synthesis, Glucose Kinetics, Energy Expenditure, Fibrosis/Collagen Turnover, Cell Proliferation, Urea Cycle, Rare Disease/Gene Therapy, and Protein Half-Life assays. It also sells non-invasive GI breath tests for sugar intolerances, SIBO, and H. pylori directly to consumers through shop.metsol.com and to GI clinics and hospitals through a provider channel under the Gut-Chek brand. All assays are delivered under GLP compliance with CLIA certification and 21 CFR Part 11 validated data handling.

Product overview

Metabolic Solutions is a laboratory services company specializing in stable isotope tracer analysis for metabolic research and drug development. The core offering is a comprehensive suite of validated stable isotope-based assays utilizing carbon-13 (13C), nitrogen-15 (15N), deuterium (2H), and oxygen-18 (18O) tracers. These services are organized into two main divisions: (1) Research Services for pharma/biotech clients including De Novo Lipogenesis, Muscle Protein Synthesis, Glucose Kinetics, Energy Expenditure, Total Body Water, Amino Acid/Protein Turnover, Cell Proliferation, Fibrosis/Collagen Turnover, Rare Disease/Gene Therapy, and Protein Half-Life assays; and (2) GI Breath Tests for clinical diagnostics including hydrogen/methane breath tests for SIBO, lactose intolerance, fructose malabsorption, H. pylori, and intestinal permeability. The company also offers a proprietary methodology called Deuteromics enabling simultaneous measurement of glucose, lipid, and protein flux via single-dose D2O administration. All assays are provided under GLP compliance with CLIA certification and 21 CFR Part 11 validated data handling.

Differentiator

Problem solved

Functional benefit

Brands

• Gut-Chek: Consumer-facing brand for at-home breath test kits for GI diagnostics including SIBO, lactose intolerance, and fructose malabsorption testing.

Products and services

• Stable Isotope Research & Analysis Services Laboratory services applying stable isotope tracers (carbon-13, nitrogen-15, deuterium, oxygen-18) analyzed via GCC-IRMS to generate regulatory-ready metabolic biomarker data for pharmaceutical and biotech drug development across discovery, preclinical, and clinical stages.
• De Novo Lipogenesis (DNL) Assay Stable isotope tracer assay that quantifies the conversion of carbohydrates into fatty acids in the liver, providing insights into hepatic lipid synthesis and metabolic health for metabolic disease and obesity drug programs.
• Muscle Protein Synthesis Assay Quantifies in vivo muscle protein synthesis rates using deuterium oxide labeling and mass spectrometry, used in studies of exercise, muscle wasting, sarcopenia, and muscle growth.
• Glucose Kinetics Assay Employs stable isotope-labeled glucose to quantify glucose flux, turnover, and whole-body glucose homeostasis under metabolic perturbations for diabetes, obesity, and metabolic disease research.
• Energy Expenditure Measurement Uses the doubly labeled water stable isotope method (deuterium oxide and oxygen-18) to measure energy expenditure in free-living humans or animals, including in academic medical center collaborations such as the Mayo Clinic.
• Total Body Water Analysis Determines total body water and fluid volume homeostasis using deuterium oxide (D2O) and oxygen-18 stable isotope methods for body composition and metabolic research.
• Amino Acid / Protein Turnover Assay Studies amino acid metabolism and whole-body/muscle protein turnover using 15N-glycine and mass spectrometry for nutrition, muscle, and metabolic research.
• Cell Proliferation Assay Quantifies in vivo DNA synthesis and cellular growth by measuring deoxyribose enrichment after D2O labeling, used in oncology research.
• Fibrosis & Collagen Turnover Assay Measures newly synthesized tissue collagen using deuterium oxide labeling and mass spectrometry to detect antifibrotic drug activity weeks before histology, used in fibrosis programs with customers including Genentech, Regeneron, Amgen, Insitro, and TNO.
• Urea Cycle Disorder Testing Quantifies restored enzyme activity in rare metabolic conditions and supports gene therapy programs for urea cycle disorder research.
• Rare Disease & Gene Therapy Endpoint Studies Supports gene therapy drug development by measuring metabolic endpoints in rare metabolic conditions, providing quantitative in vivo evidence of restored enzyme activity.
• End Product Nitrogen Metabolism Determines ammonia/nitrogen metabolism using 15N-lactose ureide and evaluates amino acid disorders such as phenylketonuria.
• Targeted Protein Half-Life Assay Quantifies in vivo protein synthesis, degradation, and half-life using D2O-based isotopic labeling and mass spectrometry for protein turnover and targeted protein degrader research.
• Non-Invasive Breath Tests Validated non-invasive breath tests measuring 13C conversion to 13CO2 and bacterial hydrogen/methane to assess liver function, gastric motility, SIBO, lactose intolerance, H. pylori, fructose malabsorption, and intestinal permeability for pharma trials and clinical research.
• Gut-Chek GI Breath Tests (Direct-to-Consumer) At-home breath test kits sold direct-to-consumer under the Gut-Chek sub-brand to detect sugar intolerances, SIBO, lactose intolerance, fructose malabsorption, and H. pylori infection, available without prescription.
• GI Breath Tests for Healthcare Providers Breath testing solutions offered to GI clinics and hospitals to assess gastrointestinal health in patients, distributed via the metsol.com provider storefront and clinical sales channel.
• Deuteromics Methodology Proprietary methodology using single-dose deuterium oxide (D2O) administration combined with GCC-IRMS analysis to simultaneously measure glucose, lipid, and protein flux without requiring constant infusion of isotope tracers, offered as part of Metabolic Solutions' research services.
• GCC-IRMS Stable Isotope Analysis Gas chromatography combustion isotope ratio mass spectrometry (GCC-IRMS) service providing high-precision measurement of stable isotope enrichment at detection levels as low as 0.001% deuterium, available across all stable isotope research and clinical applications.

Quantifiable outcome

• Protocol design support in 48 hours and results delivered weeks faster than CROs
• +2 more outcomes

Named customers15 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Scale indicators3 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• Celerion: Clinical pharmacology and bioanalytical CRO offering PK/PD, ADME, and biomarker services to pharma — directly comparable specialty bioanalytical capabilities with overlapping customer base in metabolic and early-phase drug development.
• Metabolon: Metabolomics services CRO providing metabolic biomarker analysis for pharma/biotech and academic customers — directly competing in mechanistic metabolic readouts, including lipid and energy-metabolism endpoints that overlap Metabolic Solutions' DNL and flux assays.
• BioAgilytix: Bioanalytical CRO specializing in PK/PD, immunogenicity, and biomarker assays for pharma — competing specialty bioanalytical work with similar GLP/regulated assay positioning and overlapping customer profile.
• Commonwealth Diagnostics International (CDI): GI breath testing provider offering hydrogen/methane breath tests (SIBO, lactose intolerance, fructose malabsorption) for clinicians and patients — directly competing with the Gut-Chek consumer and provider breath test franchise.

Broad incumbents

• Eurofins Scientific: Global large-scale CRO and bioanalytical laboratory network offering PK, bioanalytical, and biomarker services — comparable through its regulated lab services franchise though it serves a much broader testing menu than the niche stable isotope focus.
• LabCorp Drug Development (formerly Covance): Large central-labs and bioanalytical CRO serving global pharma across clinical and preclinical development — directly comparable in regulated bioanalytical and biomarker services with much broader scale and footprint.
• ICON plc: Top-tier global CRO with significant bioanalytical lab capabilities serving large pharma — overlapping customer base and comparable regulated lab services, though at considerably broader portfolio scope.
• Charles River Laboratories: Preclinical and bioanalytical CRO providing regulated lab services to pharma/biotech — overlapping in early-stage mechanistic and PK/PD work relevant to Metabolic Solutions' preclinical-to-clinical translational focus.
• Worldwide Clinical Trials: Mid-to-large CRO with bioanalytical and early-phase services for pharma — comparable through its scientific depth in regulated bioanalytical work and similar customer profile in metabolic and CNS drug programs.

Others

• Cambridge Isotope Laboratories: Leading supplier of stable isotopes (C-13, N-15, D, O-18) and labeled compounds used in tracer studies — enabling ecosystem peer rather than a competitor, supplying the core raw materials Metabolic Solutions depends on for its assay services.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/info_metsol
• LinkedInlinkedin.com/company/metabolic-solutions-inc-

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Metabolic Solutions